Sign Up to like & get
recommendations!
1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz260.069
Abstract: Abstract Background ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALK+ patients…
read more here.
Keywords:
alk patients;
ple patients;
patients ple;
patients alk ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Global Oncology"
DOI: 10.1200/jgo.19.00024
Abstract: PURPOSE The overall survival (OS) results in patients with ALK-positive metastatic non–small-cell lung cancer (NSCLC) have rarely been reported. The aim of this prospective-retrospective cohort study was to obtain real-world data on the use of…
read more here.
Keywords:
metastatic non;
alk positive;
cancer;
positive metastatic ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Genetics"
DOI: 10.3389/fgene.2022.772090
Abstract: Objective: To identify CT imaging biomarkers based on radiomic features for predicting brain metastases (BM) in patients with ALK-rearranged non-small cell lung cancer (NSCLC). Methods: NSCLC patients with pathologically confirmed ALK rearrangement from January 2014…
read more here.
Keywords:
patients alk;
brain metastases;
alk rearranged;
metastases patients ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2019.01116
Abstract: Purpose: Our study aimed to provide data on effectiveness, safety of crizotinib treatment, brain metastases, progression patterns, and sequential therapy beyond crizotinib treatment in patients with advanced ALK-positive NSCLC in China. Methods: We reviewed the…
read more here.
Keywords:
alk rearrangement;
patients alk;
crizotinib;
crizotinib treatment ... See more keywords